Volume 81, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


We evaluated whether sex affects the steady-state pharmacokinetics of the antimalarial drugs, primaquine and doxycycline, in healthy subjects. Seventeen male and 17 female healthy Vietnamese subjects were administered 30 mg (base) of primaquine daily for 14 days. After a 2-week washout period, 14 male and 14 female subjects were administered 100 mg (base) of doxycycline daily for 14 days. Women had significantly higher median values of (212 versus 122 ng/mL, < 0.001) and AUC (1,909 versus 917 ng · h/mL, < 0.001) of primaquine compared with men. Other than a longer in women, no sex-related differences were seen in the pharmacokinetics of doxycycline. The primaquine pharmacokinetic data suggest that women have increased exposure to primaquine, which may put them at increased risk for toxicity when administered the same maintenance dose as men. The similar pharmacokinetics of doxycycline between the two sexes justifies the same maintenance dose.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. World Health Organization, Guidelines for the treatment of malaria. Available at: http://www.who.int/malaria. Accessed June 15, 2009.
  2. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, 2006. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75: 402–415. [Google Scholar]
  3. Carson PE, 1984. 8-Aminoquinolines. Peters W, Richards WHG, eds. Antimalarial Drugs II. Current Antimalarials and New Drug Developments. Heidelberg: Springer-Verlag, 83–121.
  4. Centers for Disease Control and Prevention, Malaria Prescription Drug Information for the Public. Available at: http://www.cdc.gov/malaria/travel/drugs_public.htm. Accessed June 16, 2009.
  5. Clayman CB, Arnold J, Hockwald RS, Yount EH Jr, Edgcomb JH, Alving AS, 1952. Toxicity of primaquine in Caucasians. J Am Med Assoc 149: 1563–1568. [Google Scholar]
  6. Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, Handschin J, Tang D, Sandjaja B, Tjitra E, Hadiarso L, Watt G, Wignall FS, 1997. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126: 963–972. [Google Scholar]
  7. Pang LW, Limsomwong N, Boudreau EF, Singharaj P, 1987. Doxycycline prophylaxis for falciparum malaria. Lancet 1: 1161–1164. [Google Scholar]
  8. Rieckmann KH, Powell RD, McNamara JV, Willerson D Jr, Lass L, Frischer H, Carson PE, 1971. Effects of tetracycline against chloroquine-resistant and chloroquine-sensitive Plasmodium falciparum. Am J Trop Med Hyg 20: 811–815. [Google Scholar]
  9. Shmuklarsky MJ, Boudreau EF, Pang LW, Smith JI, Schneider I, Fleckenstein L, Abdelrahim MM, Canfield CJ, Schuster B, 1994. Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. Ann Intern Med 120: 294–299. [Google Scholar]
  10. Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Charoenlarp P, Canfield CJ, Kyle DE, 1994. Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria. Am J Trop Med Hyg 50: 784–789. [Google Scholar]
  11. Wyler DJ, 1993. Malaria chemoprophylaxis for the traveler. N Engl J Med 329: 31–37. [Google Scholar]
  12. Elmes NJ, Bennett SM, Abdalla H, Carthew TL, Edstein MD, 2006. Lack of sex effect on the pharmacokinetics of primaquine. Am J Trop Med Hyg 74: 951–952. [Google Scholar]
  13. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH, Edstein MD, 2006. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol 61: 682–689. [Google Scholar]
  14. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM, 1985. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol 19: 745–750. [Google Scholar]
  15. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM, 1984. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol 17: 441–446. [Google Scholar]
  16. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme ML, Breckenridge AM, 1985. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol 19: 751–755. [Google Scholar]
  17. Kim YR, Kuh HJ, Kim MY, Kim YS, Chung WC, Kim SI, Kang MW, 2004. Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. Arch Pharm Res 27: 576–580. [Google Scholar]
  18. Singhasivanon V, Sabcharoen A, Attanath P, Chongsuphajaisiddhi T, Diquet B, Turk P, 1991. Pharmacokinetics of primaquine in healthy volunteers. Southeast Asian J Trop Med Public Health 22: 527–533. [Google Scholar]
  19. Brueckner RP, Ohrt C, Baird K, Milhous WK, 2000. 8-aminoquinolines. Rosenthal PJ, ed. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Totowa, NJ: Humana Press, 123–151.
  20. Agwuh KN, MacGowan A, 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256–265. [Google Scholar]
  21. Saivin S, Houin G, 1988. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15: 355–366. [Google Scholar]
  22. Edstein MD, Baird JK, Fryauff DJ, Ling J, Charles BG, Population pharmacokinetics of primaquine used daily by Javanese transmigrants for malaria prophylaxis. 51st Annual Meeting of American Society of Tropical Medicine and Hygiene, Denver, CO, November 10–14, 2002.
  23. Bocker R, Muhlberg W, Platt D, Estler CJ, 1986. Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients. Eur J Clin Pharmacol 30: 105–108. [Google Scholar]
  24. CollaGenex Pharmaceuticals, 1997. NDA, New Drug Application 50-744. Submitted by CollaGenex Pharmaceuticals for Periostat.
  25. Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, Gramzinski R, Sismadi P, Krisin, Ling J, Wiady I, Kusumaningsih M, Jones TR, Fryauff DJ, Hoffman SL, and the United States Naval Medical Research Unit 2 Clinical Trials Team, 2001. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 33: 1990–1997. [Google Scholar]
  26. Harris RZ, Benet LZ, Schwartz JB, 1995. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50: 222–239. [Google Scholar]
  27. Meibohm B, Beierle I, Derendorf H, 2002. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41: 329–342. [Google Scholar]
  28. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF, 2004. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44: 499–523. [Google Scholar]
  29. Kennedy E, Frischer H, 1990. Distribution of primaquine in human blood: drug-binding to alpha 1-glycoprotein. J Lab Clin Med 116: 871–878. [Google Scholar]
  30. Routledge PA, Stargel WW, Kitchell BB, Barchowsky A, Shand DG, 1981. Sex-related differences in the plasma protein binding of lignocaine and diazepam. Br J Clin Pharmacol 11: 245–250. [Google Scholar]
  31. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM, 2003. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59: 429–442. [Google Scholar]
  32. Bangchang KN, Karbwang J, Back DJ, 1992. Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 44: 587–590. [Google Scholar]
  33. Relling MV, Lin JS, Ayers GD, Evans WE, 1992. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52: 643–658. [Google Scholar]
  34. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW, 1999. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 60: 36–40. [Google Scholar]
  35. Faber MS, Fuhr U, 2004. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76: 178–184. [Google Scholar]
  36. Rademaker M, 2001. Do women have more adverse drug reactions? Am J Clin Dermatol 2: 349–351. [Google Scholar]
  37. Baird JK, Rieckmann KH, 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19: 115–120. [Google Scholar]
  38. Baird JK, Fryauff DJ, Hoffman SL, 2003. Primaquine for prevention of malaria in travelers. Clin Infect Dis 37: 1659–1667. [Google Scholar]
  39. Baird JK, Hoffman SL, 2004. Primaquine therapy for malaria. Clin Infect Dis 39: 1336–1345. [Google Scholar]
  40. Nasveld P, Kitchener S, Edstein M, Rieckmann K, 2002. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans R Soc Trop Med Hyg 96: 683–684. [Google Scholar]

Data & Media loading...

  • Received : 24 Apr 2009
  • Accepted : 20 Jul 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error